Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Safety and immunogenicity of a prefusion non-stabilized spike protein mRNA COVID-19 vaccine: a phase I trial

14 Nov 2022

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Animal Virus Infections Studies
Share to SARS-CoV-2 and COVID-19 Research
Share to Viral Infections and Immunology Research

Source

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Identifiers

PMID: 36376393
DOI: 10.1038/s41564-022-01271-0

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Safety and immunogenicity of a prefusion non-stabilized spike protein mRNA COVID-19 vaccine: a phase I trialPMID 36376393Read ↗

A Phase1 Results of a Non-Stabilized Spike-Encoding mRNA Vaccine in AdultsSemantic proximity Read ↗

The Unique Features and Collateral Immune Effects of mRNA-Based COVID-19 Vaccines: Potential Plausible Causes of Adverse Events and ComplicationsSemantic proximity Read ↗

Efficacy, immunogenicity, and safety of a next-generation mRNA-1283 COVID-19 vaccine compared with the mRNA-1273 vaccine (NextCOVE): results from a phase 3, randomised, observer-blind, active-controlled trialSemantic proximity Read ↗

mRNA Vaccines: Design Principles, Mechanisms, and Manufacturing—Insights From COVID‐19 as a Model for Combating Infectious DiseasesSemantic proximity Read ↗

Safety and Immunogenicity of SARS-CoV-2 Spike Receptor-Binding Domain and N-Terminal Domain mRNA VaccineSemantic proximity Read ↗

Preliminary Analysis of Safety and Immunogenicity of a SARS-CoV-2 Variant Vaccine BoosterSemantic proximity Read ↗

Adverse effects of COVID-19 mRNA vaccines: the spike hypothesisSemantic proximity Read ↗

Development of SARS-CoV-2 mRNA vaccines encoding spike N-terminal and receptor binding domainsSemantic proximity Read ↗

Self-Amplifying RNA: A Second Revolution of mRNA Vaccines against COVID-19Semantic proximity Read ↗

Phase I study of a SARS-CoV-2 mRNA vaccine PTX-COVID19-BSemantic proximity Read ↗

Immunogenicity and efficacy of mRNA COVID-19 vaccine MRT5500 in preclinical animal modelsSemantic proximity Read ↗

Engineering of the current nucleoside-modified mRNA-LNP vaccines against SARS-CoV-2Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.